Skip to main content
David Graham, MD, Oncology, Charlotte, NC

David L Graham MD

Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer


Physician and Administrator at Levine Cancer Institute

Join to View Full Profile
  • 101 E W T Harris BlvdSte 1214Charlotte, NC 28262

  • Phone+1 704-863-6160

Dr. Graham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1990 - 1993
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1987 - 1990
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 1987

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2013 - 2025
  • IL State Medical License
    IL State Medical License 1993 - 2017
  • MN State Medical License
    MN State Medical License 1988 - 1994
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis
    David J. Graham, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • ASCO 2019: The Eight Biggest Stories on Anticancer Agents
    ASCO 2019: The Eight Biggest Stories on Anticancer AgentsAugust 6th, 2019
  • More Clarity to Steroids' Effect on Anti-PD-1 Therapy
    More Clarity to Steroids' Effect on Anti-PD-1 TherapyJune 27th, 2019
  • Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for mCRPC
    Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for mCRPCJune 12th, 2019
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: